Caelus' microbes for metabolic syndrome

How microbiome play Caelus is taking aim at metabolic syndrome, Type II diabetes

Of the handful of companies aiming to harness the therapeutic potential of the microbiome, Caelus Health is the first to reach the clinic with a bacterial therapeutic for metabolic syndrome: an oral formulation of Eubacterium hallii.

Caelus spun out from Academic Medical Center and Wageningen University and Research Centre in 2014 based on IP from its co-founders, Max Nieuwdorp and Willem de Vos. In a 2012 Gastroenterology paper, the co-founders' team showed fecal microbial transplant of

Read the full 757 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE